title: Exercise Improves Cognitive Impairment and Dopamine   Metabolism in MPTP-Treated Mice.
abstract: The classical motor symptoms of Parkinson’s disease (PD) are preceded by non-motor symptoms in preclinical stages, including cognition impairment. The current drug treatment for PD is palliative and does not meet the clinical challenges of the disease, such as levodopa-induced dyskinesia, non-motor symptoms, and neuroprotection. We investigated the neuroprotective and disease-modifying potential of physical exercise in a preclinical animal model of PD. C57BL/6 mice (adult males) ran on a horizontal treadmill for 6 weeks (moderate intensity, 5 times/week) and were treated intranasally with 65 mg/kg of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Exercise did not protect against MPTP-induced nigrostriatal neurodegeneration or frontostriatal dopamine depletion but decreased striatal dopamine turnover. Exercise also attenuated procedural and working memory impairment and D2 receptor hypersensitivity in MPTP-treated mice. In summary, exercise improved dopaminergic neurotransmission and enhanced cognition in a preclinical animal model of PD.
authors.forename: Aderbal S
authors.initials: AS
authors.lastname: Aguiar
authors.forename: Samantha C
authors.initials: SC
authors.lastname: Lopes
authors.forename: Fabrine S M
authors.initials: FS
authors.lastname: Tristão
authors.forename: Daniel
authors.initials: D
authors.lastname: Rial
authors.forename: Gisele
authors.initials: G
authors.lastname: de Oliveira
authors.forename: Cláudio
authors.initials: C
authors.lastname: da Cunha
authors.forename: Rita
authors.initials: R
authors.lastname: Raisman-Vozari
authors.forename: Rui D
authors.initials: RD
authors.lastname: Prediger
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D015102:3,4-Dihydroxyphenylacetic Acid; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002375:Catalepsy / Q000139:chemically induced; D003072:Cognition Disorders / Q000139:chemically induced* / Q000534:rehabilitation*; D003213:Conditioning, Psychological / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism*; D005080:Exercise Test; D005106:Exploratory Behavior / Q000187:drug effects; D005239:Fear / Q000187:drug effects; D006719:Homovanillic Acid; D008124:Locomotion / Q000187:drug effects; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D009498:Neurotoxins / Q000494:pharmacology*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
chemical_list: D009498:Neurotoxins; D015102:3,4-Dihydroxyphenylacetic Acid; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine; D006719:Homovanillic Acid